1
|
Kwatra SG, Khattri S, Amin AZ, Ranza R, Kaplan B, Shi L, Padilla B, Soliman AM, McGonagle D. Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials. Dermatol Ther (Heidelb) 2024; 14:1517-1530. [PMID: 38739215 DOI: 10.1007/s13555-024-01174-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Accepted: 04/19/2024] [Indexed: 05/14/2024] Open
Abstract
INTRODUCTION The presence (vs absence) of enthesitis/dactylitis is associated with greater psoriatic arthritis (PsA) activity and reduced health-related quality of life. Risankizumab, an interleukin 23 antagonist, demonstrated superior treatment efficacy over placebo in patients with PsA, including enthesitis/dactylitis. Herein, we report the efficacy of risankizumab on complete resolution of enthesitis and/or dactylitis and improvements in patient-reported outcomes in patients with PsA. METHODS This integrated post hoc analysis of data from KEEPsAKE 1 and KEEPsAKE 2 included patients with baseline enthesitis (Leeds Enthesitis Index > 0) and/or dactylitis (Leeds Dactylitis Index > 0). Efficacy outcomes at weeks 24 and 52 included proportion of patients achieving enthesitis and/or dactylitis resolution and minimal clinically important differences (MCID) in pain, Health Assessment Questionnaire-Disability Index, and Functional Assessment of Chronic Illness Therapy-Fatigue. RESULTS Of 1407 patients, approximately 63%, 28%, and 20% had baseline enthesitis, dactylitis, and both enthesitis/dactylitis, respectively. At week 24, higher response rates were observed for risankizumab vs placebo for resolution of enthesitis, dactylitis, and both enthesitis/dactylitis (differences of 13.9%, 16.9%, and 13.3%, respectively; p < 0.05). By week 52, risankizumab treatment resulted in complete resolution of enthesitis, dactylitis, and both enthesitis and dactylitis in 55.0%, 76.1%, and 52.3% of patients; similar resolution rates occurred among patients who switched from placebo to risankizumab. Among risankizumab-treated patients who achieved resolution of enthesitis and/or dactylitis, MCIDs were also attained in patient-reported pain, disability, and fatigue at week 24 (all p < 0.05; except fatigue in patients with resolution of both enthesitis/dactylitis); responses were sustained through week 52. CONCLUSIONS Higher proportions of risankizumab-treated (vs placebo-treated) patients achieved enthesitis and/or dactylitis resolution and meaningful improvements in patient-reported outcomes at week 24 and generally sustained responses at week 52. Thus, risankizumab may result in sustained alleviation of PsA-related pathognomonic musculoskeletal lesions of enthesitis/dactylitis. CLINICALTRIALS GOV IDENTIFIERS NCT03675308, and NCT03671148.
Collapse
Affiliation(s)
- Shawn G Kwatra
- Department of Dermatology, John Hopkins University School of Medicine, 601 N Caroline St, 8th Floor, Baltimore, MD, 21287, USA.
| | - Saakshi Khattri
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Ahmad Z Amin
- Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Roberto Ranza
- Rheumatology Unit, Hospital das Clínicas, Federal University of Uberlândia, Uberlândia, Brazil
| | | | | | | | | | - Dennis McGonagle
- Division of Rheumatology, University of Washington, Seattle, WA, USA
- Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, UK
| |
Collapse
|
2
|
Christiansen SN, Horskjær Rasmussen S, Pons M, Michelsen B, Glintborg B, Gudbjornsson B, Grondal G, Vencovsky J, Loft AG, Rotar Z, Pirkmajer KP, Nissen MJ, Baranová J, Macfarlane GJ, Jones GT, Iannone F, Caporali R, Laas K, Vorobjov S, Giuseppe DD, Olofsson T, Provan SA, Fagerli KM, Castrejon I, Otero-Varela L, van de Sande M, van der Horst-Bruinsma I, Nordström D, Kuusalo L, Bernardes M, Hetland ML, Østergaard M, Midtbøll Ørnbjerg L. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice. Semin Arthritis Rheum 2024; 65:152388. [PMID: 38301349 DOI: 10.1016/j.semarthrit.2024.152388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2023] [Revised: 01/17/2024] [Accepted: 01/18/2024] [Indexed: 02/03/2024]
Abstract
OBJECTIVES In patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) initiating secukinumab, we aimed to assess and compare the proportion of patients achieving 6-, 12- and 24-month patient-reported outcomes (PRO) remission and the 24-month retention rates. PATIENTS AND METHODS Patients with axSpA or PsA from 16 European registries, who initiated secukinumab in routine care were included. PRO remission rates were defined as pain, fatigue, Patient Global Assessment (PGA) ≤2 (Numeric Rating Scale (NRS) 0-10) and Health Assessment Questionnaire (HAQ) ≤0.5, for both axSpA and PsA, and were calculated as crude values and adjusted for drug adherence (LUNDEX). Comparisons of axSpA and PsA remission rates were performed using logistic regression analyses (unadjusted and adjusted for multiple confounders). Kaplan-Meier plots with log-rank test and Cox regression analyses were conducted to assess and compare secukinumab retention rates. RESULTS We included 3087 axSpA and 3246 PsA patients initiating secukinumab. Crude pain, fatigue, PGA and HAQ remission rates were higher in axSpA than in PsA patients, whereas LUNDEX-adjusted remission rates were similar. No differences were found between the patient groups after adjustment for confounders. The 24-month retention rates were similar in axSpA vs. PsA in fully adjusted analyses (HR [95 %CI] = 0.92 [0.84-1.02]). CONCLUSION In this large European real-world study of axSpA and PsA patients treated with secukinumab, we demonstrate for the first time a comparable effectiveness in PRO remission and treatment retention rates between these two conditions when adjusted for confounders.
Collapse
Affiliation(s)
- Sara Nysom Christiansen
- Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Valdemar Hansens Vej 17, Glostrup 2600, Denmark
| | - Simon Horskjær Rasmussen
- Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Valdemar Hansens Vej 17, Glostrup 2600, Denmark
| | - Marion Pons
- Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Valdemar Hansens Vej 17, Glostrup 2600, Denmark.
| | - Brigitte Michelsen
- Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Valdemar Hansens Vej 17, Glostrup 2600, Denmark; Research Unit, Sørlandet Hospital, Kristiansand, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway
| | - Bente Glintborg
- Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Valdemar Hansens Vej 17, Glostrup 2600, Denmark; DANBIO registry, Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Bjorn Gudbjornsson
- Centre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Reykjavik, Iceland
| | - Gerdur Grondal
- Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland
| | - Jiri Vencovsky
- Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Anne Gitte Loft
- Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
| | - Ziga Rotar
- Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
| | - Katja Perdan Pirkmajer
- Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
| | - Michael J Nissen
- Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland
| | - Jana Baranová
- Institute of Biostatistics and Analyses, Ltd, Brno, Czech Republic
| | - Gary J Macfarlane
- Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, UK
| | - Gareth T Jones
- Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, UK
| | | | - Roberto Caporali
- Department of Rheumatology and medical sciences, ASST G. Pini-CTO, Milan and University of Milan, Milan, Italy
| | - Karin Laas
- Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia
| | | | - Daniela Di Giuseppe
- Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
| | - Tor Olofsson
- Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Rheumatology, Lund, Sweden
| | - Sella Aarrestad Provan
- Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Public Health Section, Inland Norway University of Applied Sciences, Elverum, Norway
| | - Karen Minde Fagerli
- Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway
| | - Isabel Castrejon
- Department of Rheumatology, Hospital General, Universitario Gregorio Marañón, Madrid, Spain; Faculty of Medicine, Complutense, University of Madrid, Spain
| | | | - Marleen van de Sande
- Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Institute for Infection & Immunity, Amsterdam, the Netherlands; Amsterdam Rheumatology immunology Center, Reade and Amsterdam UMC, Amsterdam, the Netherlands
| | | | - Dan Nordström
- Departments of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland
| | - Laura Kuusalo
- Division of Internal Medicine, Centre for Rheumatology and Clinical Immunology, University of Turku and Turku University Hospital, Finland
| | - Miguel Bernardes
- Department of Medicine, Faculty of Medicine, University of Porto, Porto, Portugal; Rheumatology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
| | - Merete Lund Hetland
- Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Valdemar Hansens Vej 17, Glostrup 2600, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Mikkel Østergaard
- Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Valdemar Hansens Vej 17, Glostrup 2600, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Lykke Midtbøll Ørnbjerg
- Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Valdemar Hansens Vej 17, Glostrup 2600, Denmark
| |
Collapse
|
3
|
van Hal TW, Mulder MLM, Wenink MH, Vriezekolk JE. Determinants of work and social participation in patients with psoriatic arthritis in the Netherlands: an observational study. BMC Rheumatol 2022; 6:49. [PMID: 35974423 PMCID: PMC9382787 DOI: 10.1186/s41927-022-00279-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Accepted: 03/28/2022] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Psoriatic arthritis can cause pain, disability, and permanent joint damage. This can lead to impairments in work and social participation. Little is known about the extent of these impairments in routine practice. With this study, we aim to examine the extent of work and activity impairment in (subgroups of) Dutch patients with psoriatic arthritis (PsA), and to examine determinants associated with this impairment. METHODS This is an observational study using data collected from the electronic health records of PsA patients treated at the Sint Maartenskliniek, the Netherlands. Data about work and activity impairment were collected via the Work Productivity and Activity Impairment questionnaire. To compare our PsA-cohort with the Dutch general population, we used age- and sex-matched data derived from the Central Bureau of Statistics. Regression analyses were performed to examine determinants of work and activity impairment. RESULTS In total, 246 patients were included, of which 126 (51.2%) were female. Mean age (S.D.) was 55.7 (13.2) years. Compared with the Dutch general population, work for pay (WFP) was significantly lower in PsA (52.9% versus 62.6%, P < 0.001). In PsA, younger age and better physical function were associated with WFP status (P < 0.05). Higher disease activity, worse physical function, and worse mental health-related quality of life were associated with both more work and activity impairment (P < 0.05). Furthermore, reaching low disease activity status (LDA) according to Psoriatic ArthritiS Disease Activity Score (PASDAS; ≤ 3.2) was associated with less work and activity impairment than reaching LDA according to DAS28-CRP (≤ 2.9) (P < 0.05). CONCLUSIONS In PsA patients, worse physical function was associated with a lower likelihood of having WFP, and higher work and activity impairment. PASDAS LDA as a goal for treat to target, compared to DAS28-CRP, appears to favour the reduction of work and activity impairment.
Collapse
Affiliation(s)
- Tamara W van Hal
- Department of Rheumatology, Sint Maartenskliniek, P.O. Box 9011, 6500 GM, Nijmegen, The Netherlands. .,Radboud Institute for Health Sciences (RIHS), Radboud University Medical Center, Nijmegen, The Netherlands.
| | - Michelle L M Mulder
- Department of Rheumatology, Sint Maartenskliniek, P.O. Box 9011, 6500 GM, Nijmegen, The Netherlands.,Radboud Institute for Health Sciences (RIHS), Radboud University Medical Center, Nijmegen, The Netherlands
| | - Mark H Wenink
- Department of Rheumatology, Sint Maartenskliniek, P.O. Box 9011, 6500 GM, Nijmegen, The Netherlands
| | - Johanna E Vriezekolk
- Department of Rheumatology, Sint Maartenskliniek, P.O. Box 9011, 6500 GM, Nijmegen, The Netherlands.,Department of Research, Sint Maartenskliniek, Nijmegen, The Netherlands
| |
Collapse
|
4
|
Miller J, Puravath AP, Orbai AM. Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection. J Inflamm Res 2021; 14:6975-6991. [PMID: 34949934 PMCID: PMC8691193 DOI: 10.2147/jir.s229752] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2021] [Accepted: 12/04/2021] [Indexed: 12/15/2022] Open
Abstract
Objective Ixekizumab is a monoclonal antibody targeting IL-17A and licensed for psoriasis, psoriatic arthritis (PsA) and axial spondyloarthritis. Review objectives were to summarize: 1) ixekizumab safety in people with PsA, 2) ixekizumab efficacy from Phase III randomized controlled trials, and 3) ixekizumab study participant PsA phenotypes. Methods We conducted a search in PubMed limited to phase III randomized controlled trials (RCT) and corresponding long-term extension studies where the intervention was treatment with ixekizumab in a population with PsA. Results We identified 17 publications and 13 met inclusion criteria. Injection site reactions (ISR) and allergic reactions occurred in up to 25.3% and 6.2% with ixekizumab and 4.5% and 1.85, respectively, with placebo. ISR occurred in 9.5-10.6% at 24 and 52 weeks with ixekizumab versus 3.2-3.5% with adalimumab (p < 0.01) in biologic-naïve PsA. Serious adverse events at 24 weeks occurred in 8.5% with adalimumab versus 3.5% with ixekizumab (p = 0.02), and at 52 weeks in 12.45 with adalimumab and 4.25 with ixekizumab (p < 0.01). Ixekizumab had similar efficacy to adalimumab across all PsA musculoskeletal, symptom and patient-reported outcome domains and surpassed adalimumab in psoriasis outcomes as well as all combined musculoskeletal and psoriasis outcomes. The study subject population was overwhelmingly white, balanced men-women, BMI at the obese threshold, had on average 7-year PsA duration and 15-year psoriasis duration. Disease activity was high with 7/66 swollen joints, 13/68 tender joints, 55% enthesitis, variable dactylitis (12-51%), and active psoriasis in >92%. Conclusion Ixekizumab treatment in PsA was associated with a statistically significant higher risk of injection site reactions versus placebo or adalimumab. Ixekizumab had statistically significantly fewer serious adverse events than adalimumab. Ixekizumab demonstrated efficacy for all PsA disease activity domains as well as for slowing radiographic disease progression. The main shortcoming of the ixekizumab PsA program is lack of representation of African American study participants.
Collapse
Affiliation(s)
- John Miller
- Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.,Lyme Disease Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Abin P Puravath
- Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Ana-Maria Orbai
- Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.,Psoriatic Arthritis Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| |
Collapse
|
5
|
Mulder MLM, van Hal TW, van den Hoogen FHJ, de Jong EMGJ, Vriezekolk JE, Wenink MH. Measuring disease activity in psoriatic arthritis: PASDAS implementation in a tightly monitored cohort reveals residual disease burden. Rheumatology (Oxford) 2021; 60:3165-3175. [PMID: 33331947 DOI: 10.1093/rheumatology/keaa766] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Revised: 10/10/2020] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVES We aimed to investigate the disease activity and overall disease burden of (subgroups of) patients with PsA using the Psoriatic Arthritis Disease Activity Score (PASDAS) in an already tightly monitored cohort. METHODS This is a cross-sectional study evaluating data from the first visit of 855 PsA patients after implementation of the PASDAS in our tightly monitored cohort [e.g. DAS 28 (DAS28) was provided as an anchor]. Differences in clinical outcomes between subgroups of patients using established cut-offs for disease activity status [i.e. very low (VLDA), low (LDA), moderate (MDA), and high disease activity (HDA)] were examined. RESULTS Based on the PASDAS, 53.1% of patients were in VLDA/LDA. 29.5% of patients had ≥1 swollen joint, 20.6% had ≥1 enthesitis index point and 3.0% had active dactylitis. Based on DAS28, 77.5% of the patients were in VLDA/LDA. Patients reaching both DAS28 VLDA/LDA status and PASDAS VLDA/LDA status [N = 445 (52.0%)] were compared with patients reaching only DAS28 VLDA/LDA status [N = 218 (25.5%)]. For these latter patients, significantly worse scores on separate parameters were found in measures used for PASDAS/DAS28 calculation (e.g. swollen and tender joint count and patient's visual analogue scale global disease activity) as well as other disease measures (e.g. function and inflammatory back pain). This result remained, even when the stricter VLDA cut-off was used for the DAS28. CONCLUSION PASDAS implementation uncovered relevant residual disease activity in a quarter of patients previously assessed as being in DAS28 VLDA/LDA, underscoring the potential value of PASDAS measurements in PsA clinical care.
Collapse
Affiliation(s)
- Michelle L M Mulder
- Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.,Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Tamara W van Hal
- Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.,Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Frank H J van den Hoogen
- Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.,Department of Rheumatic Diseases Radboud University Medical Center, Nijmegen, The Netherlands
| | - Elke M G J de Jong
- Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands
| | | | - Mark H Wenink
- Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands
| |
Collapse
|
6
|
Gladman D, Nash P, Goto H, Birt JA, Lin CY, Orbai AM, Kvien TK. Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis. RMD Open 2021; 6:rmdopen-2019-000928. [PMID: 31958274 PMCID: PMC7046948 DOI: 10.1136/rmdopen-2019-000928] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2019] [Revised: 09/27/2019] [Accepted: 10/22/2019] [Indexed: 01/21/2023] Open
Abstract
Objectives This study assessed the psychometric properties of the fatigue numeric rating scale (NRS) and sought to establish values for clinically meaningful change (responder definition). Methods Using disease-specific clinician-reported and patient-reported data from two randomised clinical trials of patients with psoriatic arthritis (PsA), the fatigue NRS was evaluated for test–retest reliability, construct validity and responsiveness. A responder definition was also explored using anchor-based and distribution-based methods. Results Test–retest reliability analyses supported the reproducibility of the fatigue NRS in patients with PsA (intraclass correlation coefficient=0.829). Mean (SD) values at baseline and week 2 were 5.7 (2.2) and 5.7 (2.4), respectively. Supporting construct validity of the fatigue NRS, moderate-to-large correlations with other assessments measuring similar concepts as measured by Sackett’s conventions were demonstrated. Fatigue severity was reduced when the underlying disease activity was improved and reductions remained consistent at week 12 and 24. A 3-point improvement was identified as being optimal for demonstrating a level of clinically meaningful improvement in fatigue NRS after 12–24 weeks of treatment. Conclusions Fatigue NRS is a valid and responsive patient-reported outcome instrument for use in patients with PsA. The established psychometric properties from this study support the use of fatigue NRS in clinical trials and in routine clinical practice. Robust validation of reliability for use in routine clinical practice in treating patients with active PsA in less active disease states and other more diverse ethnic groups is needed.
Collapse
Affiliation(s)
- Dafna Gladman
- Medicine/Rheumatology, Krembil Research Institute, Toronto, Ontario, Canada
| | - Peter Nash
- Department of Medicine, Griffith University, Brisbane, Queensland, Australia
| | | | - Julie A Birt
- Eli Lilly and Company, Indianapolis, Indiana, USA
| | - Chen-Yen Lin
- Eli Lilly and Company, Indianapolis, Indiana, USA
| | - Ana-Maria Orbai
- Medicine Rheumatology, Johns Hopkisn University, Baltimore, Maryland, USA
| | | |
Collapse
|
7
|
Meissner Y, Rudi T, Fischer-Betz R, Strangfeld A. Pregnancy in women with psoriatic arthritis: A systematic literature review of disease activity and adverse pregnancy outcomes. Semin Arthritis Rheum 2021; 51:530-538. [PMID: 33887551 DOI: 10.1016/j.semarthrit.2021.04.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Revised: 03/25/2021] [Accepted: 04/06/2021] [Indexed: 01/20/2023]
Abstract
BACKGROUND There is limited robust evidence on the course of pregnancy and its outcomes in women with psoriatic arthritis (PsA) on which to base recommendations for the management of these patients. OBJECTIVE The primary objective was to review available data on (I) disease activity during pregnancy and on (II) adverse pregnancy outcomes (APO) in women with PsA. Secondly, neonatal outcomes and treatment of the rheumatic disease were investigated. METHODS Systematic literature search within the databases Pubmed and Embase until 30 Nov 2020 was performed. Additionally, reference lists of included studies and of review articles revealed by the search were screened. All full text articles identified and published in English language were systematically evaluated by two reviewers. All studies that reported on one of the primary outcomes and included at least five pregnancies in women with PsA were considered. RESULTS The review of 734 search results revealed 13 eligible publications reporting on a total of 2,332 pregnancies in women with PsA. Nine studies reported on PsA activity and showed an increase or worsening of disease activity after delivery compared to the pregnancy period. APOs were reported by nine studies. Adjusted analyses of APOs did not show an increased risk for gestational diabetes, small for gestational age and low birth weight in PsA patients in relation to the respective comparator groups. However, there were signals for a higher pre-eclampsia, elective caesarean section and preterm birth risk in PsA pregnancies. Meta-analysis was not performed due to study heterogeneity. DISCUSSION This review showed a postpartum deterioration of disease activity in women with PsA and no risk elevation for gestational diabetes, small for gestational age and low birth weight. A higher risk for pre-eclampsia, elective caesarean section and preterm birth in PsA pregnancies cannot be ruled out. Differences in the studies investigated limit overall summary statements on disease activity and APOs in women with PsA. Harmonization of study approaches, instruments and outcome reporting is crucial to ensure informed counselling of patients with PsA before, during and after pregnancy that is based on robust data. PROSPERO REGISTRATION NUMBER CRD42020162242.
Collapse
Affiliation(s)
- Yvette Meissner
- Deutsches Rheuma-Forschungszentrum Berlin, Programmbereich Epidemiologie und Versorgungsforschung, Berlin, Germany.
| | - Tatjana Rudi
- Deutsches Rheuma-Forschungszentrum Berlin, Programmbereich Epidemiologie und Versorgungsforschung, Berlin, Germany
| | - Rebecca Fischer-Betz
- Heinrich-Heine-Universität Düsseldorf, Poliklinik für Rheumatologie Düsseldorf and Universitätsklinikum Düsseldorf, Hiller Forschungszentrum, Düsseldorf, Germany
| | - Anja Strangfeld
- Deutsches Rheuma-Forschungszentrum Berlin, Programmbereich Epidemiologie und Versorgungsforschung, Berlin, Germany
| |
Collapse
|
8
|
Leung YY, Orbai AM, de Wit M, Balanescu A, Dernis E, Soubrier M, Eder L, Smolen JS, Coates LC, Gossec L. Comparing the Patient-Reported Physical Function Outcome Measures in a Real-Life International Cohort of Patients With Psoriatic Arthritis. Arthritis Care Res (Hoboken) 2021; 73:593-602. [PMID: 31961492 PMCID: PMC7371516 DOI: 10.1002/acr.24139] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2019] [Accepted: 01/07/2020] [Indexed: 01/22/2023]
Abstract
OBJECTIVE We evaluated the psychometric properties of 3 patient-reported outcome measures to assess the physical function in psoriatic arthritis (PsA). METHODS Data were available for the Health Assessment Questionnaire disability index (HAQ DI), the 12-item Short Form instrument physical component summary (SF-12 PCS), and the Psoriatic Arthritis Impact of Disease instrument functional capacity score (PsAID-FC). Data came from a longitudinal study in 14 countries of consecutive adults with definite PsA with ≥2 years of duration. The score distribution, construct validity, responsiveness, and thresholds of meaning of the patient-reported outcome measures were evaluated. RESULTS At baseline, 414 subjects (52% male) were analyzed. The mean ± SD age was 52.4 ± 12.5 years and duration of illness was 10.9 ± 8.1 years. Ceiling effects were noted in 31% and 21% of patients for HAQ DI and PsAID-FC, respectively; floor effects were minimal. All 3 patient-reported outcome measures met a priori hypotheses for construct validity. After a median follow-up of 4.1 (interquartile range 2.7) months in 350 patients, 27%, 54%, and 18% of patients reported themselves improved, not changed, and worsened, respectively. Change scores were statistically different for groups for worsening versus no-change for all patient-reported outcome measures. PsAID-FC was more sensitive to change than the other 2 patient-reported outcome measures. Comparing groups with worsening condition to no-change, the standardized response mean square ratios were HAQ DI 29.9, SF-12 PCS 16.7, and PsAID-FC 40.1. CONCLUSION HAQ DI, SF-12 PCS, and PsAID-FC are valid measures of physical function for PsA. PsAID-FC, a single question, performed similarly to the other patient-reported outcome measures and may be an additional option to measure PsA-specific physical function.
Collapse
Affiliation(s)
- Ying Ying Leung
- Singapore General Hospital, Duke-National University of Singapore Medical School, Singapore
| | | | - Maarten de Wit
- Patient Research Partner, VU Medical Center, Amsterdam, The Netherlands
| | - Andra Balanescu
- Maria Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
| | | | | | - Lihi Eder
- Women's College Hospital, University of Toronto, Toronto, Ontario, Canada
| | | | | | - Laure Gossec
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié Salpêtrière Hospital, AP-HP, Paris, France
| |
Collapse
|
9
|
Hughes KL, Clarke M, Williamson PR. A systematic review finds Core Outcome Set uptake varies widely across different areas of health. J Clin Epidemiol 2021; 129:114-123. [PMID: 32987162 PMCID: PMC7815247 DOI: 10.1016/j.jclinepi.2020.09.029] [Citation(s) in RCA: 49] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Revised: 08/11/2020] [Accepted: 09/09/2020] [Indexed: 12/17/2022]
Abstract
OBJECTIVE The aim of our review was to bring together studies that had assessed the uptake of core outcome sets (COS) to explore the level of uptake across different COS and areas of health. STUDY DESIGN AND SETTING We examined the citations of 337 COS reports to identify studies that had assessed the uptake of a particular COS in randomized controlled trials (RCTs) or systematic reviews (SRs). RESULTS We identified 24 studies that had assessed uptake in RCTs and two studies that had assessed uptake in SRs. The studies covered a total of 17/337 (5%) COS. Uptake rates reported for RCTs varied from 0% of RCTs (gout) to 82% RCTs (rheumatoid arthritis) measuring the full COS. Studies that assessed uptake of individual core outcomes showed a wide variation in uptake between the outcomes. Suggested barriers to uptake included lack of validated measures, lack of patient and other key stakeholder involvement in COS development, and lack of awareness of the COS. CONCLUSIONS Few studies have been undertaken to assess the uptake of COS in RCTs and SRs. Further studies are needed to assess whether COS have been implemented across a wider range of disease categories and to explore the barriers and facilitators to COS uptake.
Collapse
Affiliation(s)
- Karen L Hughes
- MRC North West Hub for Trials Methodology Research, Department of Health Data Science, University of Liverpool, Block F Waterhouse Building, 1-5 Brownlow Street, Liverpool L69 3GL, United Kingdom.
| | - Mike Clarke
- Centre for Public Health, Institute of Clinical Sciences, Block B, Queen's University Belfast, Royal Victoria Hospital, Grosvenor Road, Belfast BT12 6BA, United Kingdom
| | - Paula R Williamson
- MRC North West Hub for Trials Methodology Research, Department of Health Data Science, University of Liverpool, Block F Waterhouse Building, 1-5 Brownlow Street, Liverpool L69 3GL, United Kingdom
| |
Collapse
|
10
|
Sumpton D, Bigot A, Sautenet B, Craig JC, Hassett G, Thakkar V, Tugwell P, Tong A. Scope and Consistency of Outcomes Reported in Trials of Patients With Systemic Sclerosis. Arthritis Care Res (Hoboken) 2020; 72:1449-1458. [PMID: 31309737 DOI: 10.1002/acr.24027] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Accepted: 07/09/2019] [Indexed: 12/18/2022]
Abstract
OBJECTIVE The core outcome set for trials in systemic sclerosis (SSc) was developed in 2008 and comprises 11 domains and 31 measures, leading to the development of the Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS). We aimed to assess the scope and consistency of outcomes reported in trials of SSc and the uptake of this core set and the CRISS. METHODS Medline, the Cochrane Central Register of Controlled Trials, Embase, and ClinicalTrials.gov were searched to identify randomized trials published from January 1, 2000 to April 29, 2018 in adults with limited or diffuse SSc. Outcomes and measures were recorded for each trial, classified into domains and the frequency of outcomes before after publication of the publication of the core set calculated. RESULTS From 152 trials, 4,193 outcomes were classified into 84 domains. The 3 most common domains were health-related quality of life (HRQoL) and function (59%, 130 measures), skin (47%, 59 measures), and pulmonary (45%, 168 measures). After the publication of the core outcome set, no trial reported the complete core set with adherence to each of the 11 domains, ranging from 6.1% to 54.4% and adherence to each of the 31 measures ranging from 0% to 48.1%. The 5 measures required for the CRISS were reported completely in 11% of trials. CONCLUSION Despite recognition that uniform acquisition and reporting of outcomes would enable a better evaluation of proposed SSc therapeutics, the outcome domains and measures reported in randomized trials in SSc remain very inconsistent, with little impact of the core outcome set.
Collapse
Affiliation(s)
- Daniel Sumpton
- University of Sydney, Children's Hospital at Westmead, and Concord Hospital, Sydney, New South Wales, Australia
| | - Adrien Bigot
- Service de Médecine Interne, Hôpital Bretonneau, CHRU Tours, Tours, France
| | - Benedicte Sautenet
- Service de Néphrologie, Hôpital Bretonneau, CHRU Tours and Université de Tours et Nantes, SPHERE-INSERM 1246, Tours, France
| | | | | | - Vivek Thakkar
- Liverpool Hospital and Macquarie University, Sydney, New South Wales, Australia
| | - Peter Tugwell
- University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Allison Tong
- University of Sydney and Children's Hospital at Westmead, Sydney, New South Wales, Australia
| |
Collapse
|
11
|
Ayan G, Solmaz D, Bakirci S, Tinazzi I, Omma A, Kucuksahin O, Ozisler C, Yavuz S, Bayindir O, Kimyon G, Dogru A, Tarhan EF, Can M, Kilic L, Duruoz MT, Aksu K, Kalyoncu U, Aydin SZ. Large joint and lower extremity involvement have higher impact on disease outcomes in oligoarticular psoriatic arthritis. Int J Rheum Dis 2020; 23:1094-1099. [PMID: 32567814 DOI: 10.1111/1756-185x.13887] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2020] [Revised: 05/11/2020] [Accepted: 05/24/2020] [Indexed: 11/30/2022]
Abstract
OBJECTIVE Joints with different sizes and anatomical locations can be affected in psoriatic arthritis (PsA). Our aim was to explore the effect of different joint patterns on patient-reported outcomes (PROs) in patients with mono-oligoarthritis. METHODS Within PsArt-ID (Psoriatic Arthritis- International Database), 387/1670 patients who had mono-oligoarthritis (1-4 tender and swollen joints) were enrolled in cross-sectional assessment. The joints were categorized according to their size (small/large) and location (upper/lower extremity) and PROs, physician global assessment and C-reactive protein (CRP) were compared. Analysis was made by categorizing according to joint counts (1-2 joints/ 3-4 joints). RESULTS The mean age (SD) was 46.9 (14.24) with a mean (SD) PsA duration of 3.93 (6.03) years. Within patients with 1-2 involved joints (n = 302), size of the joints only had an impact on CRP values with large joints having higher CRP (P = .005), similar to lower extremity involvement (P = .004). PROs were similar regardless of size or location if 1-2 joints were inflamed. Within patients with 3-4 involved joints (n = 85), patient global assessment (PGA), pain, fatigue and physician global assessment were higher in the group with large joints. Similarly, PGA, pain, and physician global assessment were higher in patients with lower extremity involvement as well as higher CRP values. CONCLUSION For PsA patients with 3-4 joints involved, lower extremity and large joints are associated with poorer outcomes with worse PROs, physician global assessment, and higher CRP. The size and anatomical location of the joints are less important for patients with 1-2 joints in terms of the PROs.
Collapse
Affiliation(s)
- Gizem Ayan
- Faculty of Medicine, Rheumatology, University of Ottawa, Ottawa, ON, Canada
| | - Dilek Solmaz
- Division of Rheumatology, Department of Internal Medicine, Izmir Katip Celebi University, Izmir, Turkey
| | - Sibel Bakirci
- Faculty of Medicine, Rheumatology, University of Ottawa, Ottawa, ON, Canada
| | - Ilaria Tinazzi
- Unit of Rheumatology, Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Italy
| | - Ahmet Omma
- Division of Rheumatology, Department of Internal Medicine, Ankara Numune Education and Research Hospital, Ankara, Turkey
| | - Orhan Kucuksahin
- Division of Rheumatology, Department of Internal Medicine, Ankara Yildirim Beyazit University, Ankara, Turkey
| | - Cem Ozisler
- Division of Rheumatology, Department of Internal Medicine, Diskapi Yildirim Beyazit Education and Research Hospital, Ankara, Turkey
| | - Sule Yavuz
- Division of Rheumatology, Department of Internal Medicine, Marmara University, Istanbul, Turkey
| | - Ozun Bayindir
- Division of Rheumatology, Department of Internal Medicine, Ege University, Izmir, Turkey
| | - Gezmis Kimyon
- Division of Rheumatology, Department of Internal Medicine, Mustafa Kemal University, Hatay, Turkey
| | - Atalay Dogru
- Division of Rheumatology, Department of Internal Medicine, Suleyman Demirel University, Isparta, Turkey
| | - Emine Figen Tarhan
- Division of Rheumatology, Department of Internal Medicine, Mugla Sitki Kocman University, Mugla, Turkey
| | - Meryem Can
- Division of Rheumatology, Department of Internal Medicine, Medipol University, Istanbul, Turkey
| | - Levent Kilic
- Division of Rheumatology, Department of Internal Medicine, Hacettepe University Hospital, Hacettepe University, Ankara, Turkey
| | - Mehmet Tuncay Duruoz
- Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Marmara University School of Medicine, İstanbul, Turkey
| | - Kenan Aksu
- Division of Rheumatology, Department of Internal Medicine, Ege University, Izmir, Turkey
| | - Umut Kalyoncu
- Division of Rheumatology, Department of Internal Medicine, Hacettepe University Hospital, Hacettepe University, Ankara, Turkey
| | - Sibel Zehra Aydin
- Faculty of Medicine, Rheumatology, University of Ottawa, Ottawa, ON, Canada.,The Ottawa Hospital Research Institute, Ottawa, ON, Canada
| |
Collapse
|
12
|
Wervers K, Luime JJ, Tchetverikov I, Gerards AH, Kok MR, Appels CWY, van der Graaff WL, van Groenendael JHLM, Korswagen LA, Veris-van Dieren JJ, Hazes JMW, Vis M. Comparison of disease activity measures in early psoriatic arthritis in usual care. Rheumatology (Oxford) 2020; 58:2251-2259. [PMID: 31211399 PMCID: PMC7032073 DOI: 10.1093/rheumatology/kez215] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2018] [Revised: 04/23/2019] [Indexed: 11/21/2022] Open
Abstract
Objectives To compare responsiveness and longitudinal validity of Disease Activity Score 28 (DAS28), Disease Activity index for PSoriatic Arthritis (DAPSA), Composite Psoriatic Disease Activity Index (CPDAI), Psoriatic ArthritiS Disease Activity Score (PASDAS), GRAppa Composite scorE (GRACE) and Minimal Disease Activity (MDA) in usual care PsA patients, within 1 year after diagnosis. Methods Data collected in the Dutch southwest early PsA cohort (DEPAR) were used. Responsiveness was assessed using effect size (ES), standardized response mean (SRM), and discrimination between different general health states. Longitudinal validity was tested using mixed models with outcomes health-related quality of life (HRQOL), productivity and disability. Results Responsiveness was highest for PASDAS, with ES 1.00 and SRM 0.95, lowest for DAPSA, with ES 0.73 and SRM 0.71, and in between for DAS28, CPDAI and GRACE. Differences in general health were best discriminated with PASDAS and GRACE. Patients reporting stable or worsening general health could not be distinguished by DAS28 or CPDAI. Discrimination was better using DAPSA, but worse than when using PASDAS and GRACE. Longitudinal evolvement of HRQOL and productivity had the highest association with low disease activity according to GRACE, followed by PASDAS, MDA, DAPSA, DAS28, with the lowest association for CPDAI. Conclusion PASDAS and GRACE were superior with respect to responsiveness, and together with MDA best related to longitudinal evolvement of HRQOL, productivity and disability. Responsiveness and longitudinal validity of most outcomes were inferior for DAS28, DAPSA and CPDAI. As alternatives to the continuous measure DAPSA, use of PASDAS or GRACE should be considered.
Collapse
Affiliation(s)
- Kim Wervers
- Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, The Netherlands
| | - Jolanda J Luime
- Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, The Netherlands
| | - Ilja Tchetverikov
- Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, The Netherlands
| | - Andreas H Gerards
- Department of Rheumatology, Vlietland Hospital, Schiedam, The Netherlands
| | - Marc R Kok
- Department of Rheumatology, Maasstad Hospital, Rotterdam, The Netherlands
| | | | | | | | - Lindy-Anne Korswagen
- Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, The Netherlands
| | | | - Johanna M W Hazes
- Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, The Netherlands
| | - Marijn Vis
- Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, The Netherlands
| | | |
Collapse
|
13
|
Cañete JD, Nolla JM, Queiro R, Rodríguez MJ, Ruiz M, Lizán L. Expert Consensus on a Set of Outcomes to Assess the Effectiveness of Biologic Treatment in Psoriatic Arthritis: The MERECES Study. J Rheumatol 2020; 47:1637-1643. [DOI: 10.3899/jrheum.191056] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/16/2020] [Indexed: 02/06/2023]
Abstract
Objective.To reach a consensus on the instruments to be used in clinical practice to evaluate the effectiveness of biological disease-modifying antirheumatic drug (bDMARD) treatment in patients with psoriatic arthritis (PsA) in the short to medium term (3–6 mos), and to establish the minimum health outcomes for treatment continuation.Methods.A 2-round Delphi questionnaire was developed based on both the information gathered in the literature review and 4 discussion groups. The suitability and feasibility of the proposed sets of instruments were assessed on a 7-point Likert scale. Consensus was established when at least 75% of healthcare professionals (HCP) reached agreement. To define a minimum health outcome to continue treatment, a combination of 4 disease activity states and 3 health-related quality of life states were defined for 3 hypothetical patient profiles. HCP were given a dichotomous choice (yes/no) to respond to whether they would continue treatment in each case.Results.The second round was completed by 106 HCP. Consensus was reached on the use of (1) Disease Activity in Psoriatic Arthritis + Psoriatic Arthritis Impact of Disease (PsAID12) or minimal disease activity + PsAID12 + C-reactive protein, in peripheral PsA; and (2) Ankylosing Spondylitis Disease Activity Score + PsAID12, in axial PsA. Health outcomes considered sufficient to continue treatment were stricter for bDMARD-naive patients than for patients who failed several bDMARD.Conclusion.To the best of our knowledge, this is the first multidisciplinary consensus on a set of outcomes for the evaluation of bDMARD effectiveness in PsA, in routine clinical practice.
Collapse
|
14
|
Sinnathurai P, Bartlett SJ, Halls S, Hewlett S, Orbai AM, Buchbinder R, Henderson L, Hill CL, Lassere M, March L. Investigating Dimensions of Stiffness in Rheumatoid and Psoriatic Arthritis: The Australian Rheumatology Association Database Registry and OMERACT Collaboration. J Rheumatol 2019; 46:1462-1469. [PMID: 30936277 DOI: 10.3899/jrheum.181251] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/22/2019] [Indexed: 12/24/2022]
Abstract
OBJECTIVE It is not known how the experience of stiffness varies between diagnoses or how best to measure stiffness. The aims of our study were to (1) compare stiffness in psoriatic arthritis (PsA) and rheumatoid arthritis (RA) using patient-reported outcomes, (2) investigate how dimensions of stiffness are associated with each other and reflect the patient experience, and (3) analyze how different dimensions of stiffness are associated with physical function. METHODS An online survey was sent to Australian Rheumatology Association Database participants (158 PsA, and 158 age- and sex-matched RA), assessing stiffness severity, duration, impact, importance, coping, and physical function [modified Health Assessment Questionnaire (mHAQ)]. Scores were compared between diagnoses and correlations among stiffness dimensions calculated. Multivariate regression was performed for stiffness severity, impact, and duration on mHAQ, adjusting for age, sex, disease duration, obesity, and pain. Cognitive debriefing was conducted through semistructured telephone interviews. RESULTS Overall, 240/316 (75.9%) responded [124/158 RA (78.5%) and 116/158 PsA (73.4%)], with no significant difference in stiffness ratings between diagnoses. Scores for all stiffness dimensions were strongly correlated (r = 0.52-0.89), and severity and impact were associated with mHAQ in both diagnoses. Stiffness duration was not associated with mHAQ in RA. In cognitive debriefing, participants described stiffness severity and impact by their effect on daily activities (10/16 and 14/16 participants, respectively). CONCLUSION Stiffness ratings were similar between PsA and RA. Different dimensions of stiffness were strongly correlated. Stiffness severity and impact both independently predicted mHAQ. Stiffness was important to participants; however, measuring multiple dimensions of stiffness may have minimal additive value.
Collapse
Affiliation(s)
- Premarani Sinnathurai
- From the Institute of Bone and Joint Research, Kolling Institute; Rheumatology Department, Royal North Shore Hospital, St Leonards; Sydney Medical School, University of Sydney; School of Public Health and Community Medicine, University of New South Wales, Sydney; Monash Department of Clinical Epidemiology, Cabrini Institute; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne; Rheumatology Unit, The Queen Elizabeth Hospital; Discipline of Medicine, University of Adelaide, Adelaide; Rheumatology Department, St George Hospital, Kogarah, Australia; Divisions of Clinical Epidemiology, Rheumatology, and Respiratory Epidemiology, McGill University, Montreal, Quebec, Canada; Division of Rheumatology, Johns Hopkins Medicine, Baltimore, Maryland, USA; Department of Nursing and Midwifery, University of the West of England, Bristol, UK. .,P. Sinnathurai, MBBS, Institute of Bone and Joint Research, Kolling Institute, Northern Sydney Local Health District, and Department of Rheumatology, Royal North Shore Hospital, and University of Sydney; S.J. Bartlett, MD, Division of Clinical Epidemiology, Division of Rheumatology, and Division of Respiratory Epidemiology, McGill University/McGill University Health Centers, and Division of Rheumatology, Johns Hopkins School of Medicine; S. Halls, PhD, Department of Nursing and Midwifery, University of the West of England; S. Hewlett, PhD, Department of Nursing and Midwifery, University of the West of England; A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; R. Buchbinder, PhD, Monash Department of Clinical Epidemiology, Cabrini Institute, and Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; L. Henderson, MSc, University of Sydney; C.L. Hill, MD, Rheumatology Unit, The Queen Elizabeth Hospital, and Discipline of Medicine, University of Adelaide; M. Lassere, PhD, School of Public Health and Community Medicine, University of New South Wales and Rheumatology Department, St George Hospital; L. March, PhD, Institute of Bone and Joint Research, Kolling Institute, Northern Sydney Local Health District, and Department of Rheumatology, Royal North Shore Hospital, and University of Sydney.
| | - Susan J Bartlett
- From the Institute of Bone and Joint Research, Kolling Institute; Rheumatology Department, Royal North Shore Hospital, St Leonards; Sydney Medical School, University of Sydney; School of Public Health and Community Medicine, University of New South Wales, Sydney; Monash Department of Clinical Epidemiology, Cabrini Institute; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne; Rheumatology Unit, The Queen Elizabeth Hospital; Discipline of Medicine, University of Adelaide, Adelaide; Rheumatology Department, St George Hospital, Kogarah, Australia; Divisions of Clinical Epidemiology, Rheumatology, and Respiratory Epidemiology, McGill University, Montreal, Quebec, Canada; Division of Rheumatology, Johns Hopkins Medicine, Baltimore, Maryland, USA; Department of Nursing and Midwifery, University of the West of England, Bristol, UK.,P. Sinnathurai, MBBS, Institute of Bone and Joint Research, Kolling Institute, Northern Sydney Local Health District, and Department of Rheumatology, Royal North Shore Hospital, and University of Sydney; S.J. Bartlett, MD, Division of Clinical Epidemiology, Division of Rheumatology, and Division of Respiratory Epidemiology, McGill University/McGill University Health Centers, and Division of Rheumatology, Johns Hopkins School of Medicine; S. Halls, PhD, Department of Nursing and Midwifery, University of the West of England; S. Hewlett, PhD, Department of Nursing and Midwifery, University of the West of England; A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; R. Buchbinder, PhD, Monash Department of Clinical Epidemiology, Cabrini Institute, and Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; L. Henderson, MSc, University of Sydney; C.L. Hill, MD, Rheumatology Unit, The Queen Elizabeth Hospital, and Discipline of Medicine, University of Adelaide; M. Lassere, PhD, School of Public Health and Community Medicine, University of New South Wales and Rheumatology Department, St George Hospital; L. March, PhD, Institute of Bone and Joint Research, Kolling Institute, Northern Sydney Local Health District, and Department of Rheumatology, Royal North Shore Hospital, and University of Sydney
| | - Serena Halls
- From the Institute of Bone and Joint Research, Kolling Institute; Rheumatology Department, Royal North Shore Hospital, St Leonards; Sydney Medical School, University of Sydney; School of Public Health and Community Medicine, University of New South Wales, Sydney; Monash Department of Clinical Epidemiology, Cabrini Institute; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne; Rheumatology Unit, The Queen Elizabeth Hospital; Discipline of Medicine, University of Adelaide, Adelaide; Rheumatology Department, St George Hospital, Kogarah, Australia; Divisions of Clinical Epidemiology, Rheumatology, and Respiratory Epidemiology, McGill University, Montreal, Quebec, Canada; Division of Rheumatology, Johns Hopkins Medicine, Baltimore, Maryland, USA; Department of Nursing and Midwifery, University of the West of England, Bristol, UK.,P. Sinnathurai, MBBS, Institute of Bone and Joint Research, Kolling Institute, Northern Sydney Local Health District, and Department of Rheumatology, Royal North Shore Hospital, and University of Sydney; S.J. Bartlett, MD, Division of Clinical Epidemiology, Division of Rheumatology, and Division of Respiratory Epidemiology, McGill University/McGill University Health Centers, and Division of Rheumatology, Johns Hopkins School of Medicine; S. Halls, PhD, Department of Nursing and Midwifery, University of the West of England; S. Hewlett, PhD, Department of Nursing and Midwifery, University of the West of England; A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; R. Buchbinder, PhD, Monash Department of Clinical Epidemiology, Cabrini Institute, and Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; L. Henderson, MSc, University of Sydney; C.L. Hill, MD, Rheumatology Unit, The Queen Elizabeth Hospital, and Discipline of Medicine, University of Adelaide; M. Lassere, PhD, School of Public Health and Community Medicine, University of New South Wales and Rheumatology Department, St George Hospital; L. March, PhD, Institute of Bone and Joint Research, Kolling Institute, Northern Sydney Local Health District, and Department of Rheumatology, Royal North Shore Hospital, and University of Sydney
| | - Sarah Hewlett
- From the Institute of Bone and Joint Research, Kolling Institute; Rheumatology Department, Royal North Shore Hospital, St Leonards; Sydney Medical School, University of Sydney; School of Public Health and Community Medicine, University of New South Wales, Sydney; Monash Department of Clinical Epidemiology, Cabrini Institute; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne; Rheumatology Unit, The Queen Elizabeth Hospital; Discipline of Medicine, University of Adelaide, Adelaide; Rheumatology Department, St George Hospital, Kogarah, Australia; Divisions of Clinical Epidemiology, Rheumatology, and Respiratory Epidemiology, McGill University, Montreal, Quebec, Canada; Division of Rheumatology, Johns Hopkins Medicine, Baltimore, Maryland, USA; Department of Nursing and Midwifery, University of the West of England, Bristol, UK.,P. Sinnathurai, MBBS, Institute of Bone and Joint Research, Kolling Institute, Northern Sydney Local Health District, and Department of Rheumatology, Royal North Shore Hospital, and University of Sydney; S.J. Bartlett, MD, Division of Clinical Epidemiology, Division of Rheumatology, and Division of Respiratory Epidemiology, McGill University/McGill University Health Centers, and Division of Rheumatology, Johns Hopkins School of Medicine; S. Halls, PhD, Department of Nursing and Midwifery, University of the West of England; S. Hewlett, PhD, Department of Nursing and Midwifery, University of the West of England; A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; R. Buchbinder, PhD, Monash Department of Clinical Epidemiology, Cabrini Institute, and Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; L. Henderson, MSc, University of Sydney; C.L. Hill, MD, Rheumatology Unit, The Queen Elizabeth Hospital, and Discipline of Medicine, University of Adelaide; M. Lassere, PhD, School of Public Health and Community Medicine, University of New South Wales and Rheumatology Department, St George Hospital; L. March, PhD, Institute of Bone and Joint Research, Kolling Institute, Northern Sydney Local Health District, and Department of Rheumatology, Royal North Shore Hospital, and University of Sydney
| | - Ana-Maria Orbai
- From the Institute of Bone and Joint Research, Kolling Institute; Rheumatology Department, Royal North Shore Hospital, St Leonards; Sydney Medical School, University of Sydney; School of Public Health and Community Medicine, University of New South Wales, Sydney; Monash Department of Clinical Epidemiology, Cabrini Institute; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne; Rheumatology Unit, The Queen Elizabeth Hospital; Discipline of Medicine, University of Adelaide, Adelaide; Rheumatology Department, St George Hospital, Kogarah, Australia; Divisions of Clinical Epidemiology, Rheumatology, and Respiratory Epidemiology, McGill University, Montreal, Quebec, Canada; Division of Rheumatology, Johns Hopkins Medicine, Baltimore, Maryland, USA; Department of Nursing and Midwifery, University of the West of England, Bristol, UK.,P. Sinnathurai, MBBS, Institute of Bone and Joint Research, Kolling Institute, Northern Sydney Local Health District, and Department of Rheumatology, Royal North Shore Hospital, and University of Sydney; S.J. Bartlett, MD, Division of Clinical Epidemiology, Division of Rheumatology, and Division of Respiratory Epidemiology, McGill University/McGill University Health Centers, and Division of Rheumatology, Johns Hopkins School of Medicine; S. Halls, PhD, Department of Nursing and Midwifery, University of the West of England; S. Hewlett, PhD, Department of Nursing and Midwifery, University of the West of England; A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; R. Buchbinder, PhD, Monash Department of Clinical Epidemiology, Cabrini Institute, and Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; L. Henderson, MSc, University of Sydney; C.L. Hill, MD, Rheumatology Unit, The Queen Elizabeth Hospital, and Discipline of Medicine, University of Adelaide; M. Lassere, PhD, School of Public Health and Community Medicine, University of New South Wales and Rheumatology Department, St George Hospital; L. March, PhD, Institute of Bone and Joint Research, Kolling Institute, Northern Sydney Local Health District, and Department of Rheumatology, Royal North Shore Hospital, and University of Sydney
| | - Rachelle Buchbinder
- From the Institute of Bone and Joint Research, Kolling Institute; Rheumatology Department, Royal North Shore Hospital, St Leonards; Sydney Medical School, University of Sydney; School of Public Health and Community Medicine, University of New South Wales, Sydney; Monash Department of Clinical Epidemiology, Cabrini Institute; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne; Rheumatology Unit, The Queen Elizabeth Hospital; Discipline of Medicine, University of Adelaide, Adelaide; Rheumatology Department, St George Hospital, Kogarah, Australia; Divisions of Clinical Epidemiology, Rheumatology, and Respiratory Epidemiology, McGill University, Montreal, Quebec, Canada; Division of Rheumatology, Johns Hopkins Medicine, Baltimore, Maryland, USA; Department of Nursing and Midwifery, University of the West of England, Bristol, UK.,P. Sinnathurai, MBBS, Institute of Bone and Joint Research, Kolling Institute, Northern Sydney Local Health District, and Department of Rheumatology, Royal North Shore Hospital, and University of Sydney; S.J. Bartlett, MD, Division of Clinical Epidemiology, Division of Rheumatology, and Division of Respiratory Epidemiology, McGill University/McGill University Health Centers, and Division of Rheumatology, Johns Hopkins School of Medicine; S. Halls, PhD, Department of Nursing and Midwifery, University of the West of England; S. Hewlett, PhD, Department of Nursing and Midwifery, University of the West of England; A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; R. Buchbinder, PhD, Monash Department of Clinical Epidemiology, Cabrini Institute, and Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; L. Henderson, MSc, University of Sydney; C.L. Hill, MD, Rheumatology Unit, The Queen Elizabeth Hospital, and Discipline of Medicine, University of Adelaide; M. Lassere, PhD, School of Public Health and Community Medicine, University of New South Wales and Rheumatology Department, St George Hospital; L. March, PhD, Institute of Bone and Joint Research, Kolling Institute, Northern Sydney Local Health District, and Department of Rheumatology, Royal North Shore Hospital, and University of Sydney
| | - Lyndall Henderson
- From the Institute of Bone and Joint Research, Kolling Institute; Rheumatology Department, Royal North Shore Hospital, St Leonards; Sydney Medical School, University of Sydney; School of Public Health and Community Medicine, University of New South Wales, Sydney; Monash Department of Clinical Epidemiology, Cabrini Institute; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne; Rheumatology Unit, The Queen Elizabeth Hospital; Discipline of Medicine, University of Adelaide, Adelaide; Rheumatology Department, St George Hospital, Kogarah, Australia; Divisions of Clinical Epidemiology, Rheumatology, and Respiratory Epidemiology, McGill University, Montreal, Quebec, Canada; Division of Rheumatology, Johns Hopkins Medicine, Baltimore, Maryland, USA; Department of Nursing and Midwifery, University of the West of England, Bristol, UK.,P. Sinnathurai, MBBS, Institute of Bone and Joint Research, Kolling Institute, Northern Sydney Local Health District, and Department of Rheumatology, Royal North Shore Hospital, and University of Sydney; S.J. Bartlett, MD, Division of Clinical Epidemiology, Division of Rheumatology, and Division of Respiratory Epidemiology, McGill University/McGill University Health Centers, and Division of Rheumatology, Johns Hopkins School of Medicine; S. Halls, PhD, Department of Nursing and Midwifery, University of the West of England; S. Hewlett, PhD, Department of Nursing and Midwifery, University of the West of England; A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; R. Buchbinder, PhD, Monash Department of Clinical Epidemiology, Cabrini Institute, and Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; L. Henderson, MSc, University of Sydney; C.L. Hill, MD, Rheumatology Unit, The Queen Elizabeth Hospital, and Discipline of Medicine, University of Adelaide; M. Lassere, PhD, School of Public Health and Community Medicine, University of New South Wales and Rheumatology Department, St George Hospital; L. March, PhD, Institute of Bone and Joint Research, Kolling Institute, Northern Sydney Local Health District, and Department of Rheumatology, Royal North Shore Hospital, and University of Sydney
| | - Catherine L Hill
- From the Institute of Bone and Joint Research, Kolling Institute; Rheumatology Department, Royal North Shore Hospital, St Leonards; Sydney Medical School, University of Sydney; School of Public Health and Community Medicine, University of New South Wales, Sydney; Monash Department of Clinical Epidemiology, Cabrini Institute; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne; Rheumatology Unit, The Queen Elizabeth Hospital; Discipline of Medicine, University of Adelaide, Adelaide; Rheumatology Department, St George Hospital, Kogarah, Australia; Divisions of Clinical Epidemiology, Rheumatology, and Respiratory Epidemiology, McGill University, Montreal, Quebec, Canada; Division of Rheumatology, Johns Hopkins Medicine, Baltimore, Maryland, USA; Department of Nursing and Midwifery, University of the West of England, Bristol, UK.,P. Sinnathurai, MBBS, Institute of Bone and Joint Research, Kolling Institute, Northern Sydney Local Health District, and Department of Rheumatology, Royal North Shore Hospital, and University of Sydney; S.J. Bartlett, MD, Division of Clinical Epidemiology, Division of Rheumatology, and Division of Respiratory Epidemiology, McGill University/McGill University Health Centers, and Division of Rheumatology, Johns Hopkins School of Medicine; S. Halls, PhD, Department of Nursing and Midwifery, University of the West of England; S. Hewlett, PhD, Department of Nursing and Midwifery, University of the West of England; A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; R. Buchbinder, PhD, Monash Department of Clinical Epidemiology, Cabrini Institute, and Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; L. Henderson, MSc, University of Sydney; C.L. Hill, MD, Rheumatology Unit, The Queen Elizabeth Hospital, and Discipline of Medicine, University of Adelaide; M. Lassere, PhD, School of Public Health and Community Medicine, University of New South Wales and Rheumatology Department, St George Hospital; L. March, PhD, Institute of Bone and Joint Research, Kolling Institute, Northern Sydney Local Health District, and Department of Rheumatology, Royal North Shore Hospital, and University of Sydney
| | - Marissa Lassere
- From the Institute of Bone and Joint Research, Kolling Institute; Rheumatology Department, Royal North Shore Hospital, St Leonards; Sydney Medical School, University of Sydney; School of Public Health and Community Medicine, University of New South Wales, Sydney; Monash Department of Clinical Epidemiology, Cabrini Institute; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne; Rheumatology Unit, The Queen Elizabeth Hospital; Discipline of Medicine, University of Adelaide, Adelaide; Rheumatology Department, St George Hospital, Kogarah, Australia; Divisions of Clinical Epidemiology, Rheumatology, and Respiratory Epidemiology, McGill University, Montreal, Quebec, Canada; Division of Rheumatology, Johns Hopkins Medicine, Baltimore, Maryland, USA; Department of Nursing and Midwifery, University of the West of England, Bristol, UK.,P. Sinnathurai, MBBS, Institute of Bone and Joint Research, Kolling Institute, Northern Sydney Local Health District, and Department of Rheumatology, Royal North Shore Hospital, and University of Sydney; S.J. Bartlett, MD, Division of Clinical Epidemiology, Division of Rheumatology, and Division of Respiratory Epidemiology, McGill University/McGill University Health Centers, and Division of Rheumatology, Johns Hopkins School of Medicine; S. Halls, PhD, Department of Nursing and Midwifery, University of the West of England; S. Hewlett, PhD, Department of Nursing and Midwifery, University of the West of England; A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; R. Buchbinder, PhD, Monash Department of Clinical Epidemiology, Cabrini Institute, and Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; L. Henderson, MSc, University of Sydney; C.L. Hill, MD, Rheumatology Unit, The Queen Elizabeth Hospital, and Discipline of Medicine, University of Adelaide; M. Lassere, PhD, School of Public Health and Community Medicine, University of New South Wales and Rheumatology Department, St George Hospital; L. March, PhD, Institute of Bone and Joint Research, Kolling Institute, Northern Sydney Local Health District, and Department of Rheumatology, Royal North Shore Hospital, and University of Sydney
| | - Lyn March
- From the Institute of Bone and Joint Research, Kolling Institute; Rheumatology Department, Royal North Shore Hospital, St Leonards; Sydney Medical School, University of Sydney; School of Public Health and Community Medicine, University of New South Wales, Sydney; Monash Department of Clinical Epidemiology, Cabrini Institute; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne; Rheumatology Unit, The Queen Elizabeth Hospital; Discipline of Medicine, University of Adelaide, Adelaide; Rheumatology Department, St George Hospital, Kogarah, Australia; Divisions of Clinical Epidemiology, Rheumatology, and Respiratory Epidemiology, McGill University, Montreal, Quebec, Canada; Division of Rheumatology, Johns Hopkins Medicine, Baltimore, Maryland, USA; Department of Nursing and Midwifery, University of the West of England, Bristol, UK.,P. Sinnathurai, MBBS, Institute of Bone and Joint Research, Kolling Institute, Northern Sydney Local Health District, and Department of Rheumatology, Royal North Shore Hospital, and University of Sydney; S.J. Bartlett, MD, Division of Clinical Epidemiology, Division of Rheumatology, and Division of Respiratory Epidemiology, McGill University/McGill University Health Centers, and Division of Rheumatology, Johns Hopkins School of Medicine; S. Halls, PhD, Department of Nursing and Midwifery, University of the West of England; S. Hewlett, PhD, Department of Nursing and Midwifery, University of the West of England; A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; R. Buchbinder, PhD, Monash Department of Clinical Epidemiology, Cabrini Institute, and Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; L. Henderson, MSc, University of Sydney; C.L. Hill, MD, Rheumatology Unit, The Queen Elizabeth Hospital, and Discipline of Medicine, University of Adelaide; M. Lassere, PhD, School of Public Health and Community Medicine, University of New South Wales and Rheumatology Department, St George Hospital; L. March, PhD, Institute of Bone and Joint Research, Kolling Institute, Northern Sydney Local Health District, and Department of Rheumatology, Royal North Shore Hospital, and University of Sydney
| |
Collapse
|
15
|
Elmamoun M, Leung YY, O'Sullivan D, Steinkoenig I, Chandran V, Gladman DD, FitzGerald OM, Orbai AM, Eder L. Using Acute-phase Reactants to Inform the Development of Instruments for the Updated Psoriatic Arthritis Core Outcome Measurement Set. J Rheumatol 2018; 46:266-273. [PMID: 30385708 DOI: 10.3899/jrheum.180195] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/03/2018] [Indexed: 02/08/2023]
Abstract
OBJECTIVE Systemic inflammationˆ is assessed through measurement of acute-phase reactants such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). With few exceptions, most randomized controlled trials (RCT) have assessed acute-phase reactants (CRP and ESR) as part of the American College of Rheumatology (ACR) 20 response criteria. As part of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) working group, we performed a systematic review of the literature to assess the performance of inflammatory biomarkers in psoriatic arthritis (PsA). METHODS A systematic search of PubMed and Embase was performed. The search included peer-reviewed articles and scientific meeting abstracts about RCT and longitudinal observational studies that assessed systemic inflammation using acute-phase reactants in PsA. Studies were assessed following the components of the OMERACT filter including construct validity, responsiveness, and predictive validity. RESULTS There were 2764 articles retrieved, and 71 articles were included for this systematic review. Twenty-eight articles reported CRP and/or ESR separately, and the remaining articles reported CRP and/or ESR as part of the ACR response criteria. Studies assessing OMERACT responsiveness provided conflicting reports. Inflammatory biomarkers had construct validity for more active disease. Evidence suggests that an elevation of ESR predicts cardiovascular outcomes. CONCLUSION Data regarding assessment of systemic inflammation using acute-phase reactants (CRP and ESR) are limited. There is only weak evidence to support normalization of these biomarkers in predicting good clinical outcomes/remission criteria. The predictive value for cardiovascular outcomes was generally good. Further studies to assess systemic inflammation in PsA using acute-phase reactants and other laboratory biomarkers are needed.
Collapse
Affiliation(s)
- Musaab Elmamoun
- From the Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland; Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology and Immunology, Singapore General Hospital; Duke-NUS Medical School, Singapore; University Hospitals, Cleveland, Ohio, USA; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland, USA; Women's College Research Institute, Women's College Hospital; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.,M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; Y.Y. Leung, MBChB, MD, Department of Rheumatology and Immunology, Singapore General Hospital, and Duke-NUS Medical School; D. O'Sullivan, BE, Patient Research Partner, St. Vincent's University Hospital; I. Steinkoenig, BA, Patient Research Partner, University Hospitals; V. Chandran, MBBS, MD, DM, PhD, Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; D.D. Gladman, MD, FRCPC, Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; O.M. FitzGerald, MD, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; A.M. Orbai, MD, MHS, Johns Hopkins University School of Medicine, Division of Rheumatology; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, and Department of Medicine, University of Toronto
| | - Ying Ying Leung
- From the Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland; Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology and Immunology, Singapore General Hospital; Duke-NUS Medical School, Singapore; University Hospitals, Cleveland, Ohio, USA; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland, USA; Women's College Research Institute, Women's College Hospital; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.,M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; Y.Y. Leung, MBChB, MD, Department of Rheumatology and Immunology, Singapore General Hospital, and Duke-NUS Medical School; D. O'Sullivan, BE, Patient Research Partner, St. Vincent's University Hospital; I. Steinkoenig, BA, Patient Research Partner, University Hospitals; V. Chandran, MBBS, MD, DM, PhD, Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; D.D. Gladman, MD, FRCPC, Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; O.M. FitzGerald, MD, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; A.M. Orbai, MD, MHS, Johns Hopkins University School of Medicine, Division of Rheumatology; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, and Department of Medicine, University of Toronto
| | - Denis O'Sullivan
- From the Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland; Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology and Immunology, Singapore General Hospital; Duke-NUS Medical School, Singapore; University Hospitals, Cleveland, Ohio, USA; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland, USA; Women's College Research Institute, Women's College Hospital; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.,M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; Y.Y. Leung, MBChB, MD, Department of Rheumatology and Immunology, Singapore General Hospital, and Duke-NUS Medical School; D. O'Sullivan, BE, Patient Research Partner, St. Vincent's University Hospital; I. Steinkoenig, BA, Patient Research Partner, University Hospitals; V. Chandran, MBBS, MD, DM, PhD, Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; D.D. Gladman, MD, FRCPC, Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; O.M. FitzGerald, MD, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; A.M. Orbai, MD, MHS, Johns Hopkins University School of Medicine, Division of Rheumatology; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, and Department of Medicine, University of Toronto
| | - Ingrid Steinkoenig
- From the Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland; Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology and Immunology, Singapore General Hospital; Duke-NUS Medical School, Singapore; University Hospitals, Cleveland, Ohio, USA; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland, USA; Women's College Research Institute, Women's College Hospital; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.,M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; Y.Y. Leung, MBChB, MD, Department of Rheumatology and Immunology, Singapore General Hospital, and Duke-NUS Medical School; D. O'Sullivan, BE, Patient Research Partner, St. Vincent's University Hospital; I. Steinkoenig, BA, Patient Research Partner, University Hospitals; V. Chandran, MBBS, MD, DM, PhD, Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; D.D. Gladman, MD, FRCPC, Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; O.M. FitzGerald, MD, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; A.M. Orbai, MD, MHS, Johns Hopkins University School of Medicine, Division of Rheumatology; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, and Department of Medicine, University of Toronto
| | - Vinod Chandran
- From the Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland; Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology and Immunology, Singapore General Hospital; Duke-NUS Medical School, Singapore; University Hospitals, Cleveland, Ohio, USA; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland, USA; Women's College Research Institute, Women's College Hospital; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.,M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; Y.Y. Leung, MBChB, MD, Department of Rheumatology and Immunology, Singapore General Hospital, and Duke-NUS Medical School; D. O'Sullivan, BE, Patient Research Partner, St. Vincent's University Hospital; I. Steinkoenig, BA, Patient Research Partner, University Hospitals; V. Chandran, MBBS, MD, DM, PhD, Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; D.D. Gladman, MD, FRCPC, Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; O.M. FitzGerald, MD, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; A.M. Orbai, MD, MHS, Johns Hopkins University School of Medicine, Division of Rheumatology; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, and Department of Medicine, University of Toronto
| | - Dafna D Gladman
- From the Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland; Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology and Immunology, Singapore General Hospital; Duke-NUS Medical School, Singapore; University Hospitals, Cleveland, Ohio, USA; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland, USA; Women's College Research Institute, Women's College Hospital; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.,M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; Y.Y. Leung, MBChB, MD, Department of Rheumatology and Immunology, Singapore General Hospital, and Duke-NUS Medical School; D. O'Sullivan, BE, Patient Research Partner, St. Vincent's University Hospital; I. Steinkoenig, BA, Patient Research Partner, University Hospitals; V. Chandran, MBBS, MD, DM, PhD, Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; D.D. Gladman, MD, FRCPC, Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; O.M. FitzGerald, MD, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; A.M. Orbai, MD, MHS, Johns Hopkins University School of Medicine, Division of Rheumatology; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, and Department of Medicine, University of Toronto
| | - Oliver M FitzGerald
- From the Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland; Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology and Immunology, Singapore General Hospital; Duke-NUS Medical School, Singapore; University Hospitals, Cleveland, Ohio, USA; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland, USA; Women's College Research Institute, Women's College Hospital; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.,M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; Y.Y. Leung, MBChB, MD, Department of Rheumatology and Immunology, Singapore General Hospital, and Duke-NUS Medical School; D. O'Sullivan, BE, Patient Research Partner, St. Vincent's University Hospital; I. Steinkoenig, BA, Patient Research Partner, University Hospitals; V. Chandran, MBBS, MD, DM, PhD, Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; D.D. Gladman, MD, FRCPC, Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; O.M. FitzGerald, MD, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; A.M. Orbai, MD, MHS, Johns Hopkins University School of Medicine, Division of Rheumatology; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, and Department of Medicine, University of Toronto
| | - Ana-Maria Orbai
- From the Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland; Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology and Immunology, Singapore General Hospital; Duke-NUS Medical School, Singapore; University Hospitals, Cleveland, Ohio, USA; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland, USA; Women's College Research Institute, Women's College Hospital; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.,M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; Y.Y. Leung, MBChB, MD, Department of Rheumatology and Immunology, Singapore General Hospital, and Duke-NUS Medical School; D. O'Sullivan, BE, Patient Research Partner, St. Vincent's University Hospital; I. Steinkoenig, BA, Patient Research Partner, University Hospitals; V. Chandran, MBBS, MD, DM, PhD, Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; D.D. Gladman, MD, FRCPC, Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; O.M. FitzGerald, MD, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; A.M. Orbai, MD, MHS, Johns Hopkins University School of Medicine, Division of Rheumatology; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, and Department of Medicine, University of Toronto
| | - Lihi Eder
- From the Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland; Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology and Immunology, Singapore General Hospital; Duke-NUS Medical School, Singapore; University Hospitals, Cleveland, Ohio, USA; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland, USA; Women's College Research Institute, Women's College Hospital; Department of Medicine, University of Toronto, Toronto, Ontario, Canada. .,M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; Y.Y. Leung, MBChB, MD, Department of Rheumatology and Immunology, Singapore General Hospital, and Duke-NUS Medical School; D. O'Sullivan, BE, Patient Research Partner, St. Vincent's University Hospital; I. Steinkoenig, BA, Patient Research Partner, University Hospitals; V. Chandran, MBBS, MD, DM, PhD, Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; D.D. Gladman, MD, FRCPC, Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto Western Hospital; O.M. FitzGerald, MD, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; A.M. Orbai, MD, MHS, Johns Hopkins University School of Medicine, Division of Rheumatology; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, and Department of Medicine, University of Toronto.
| |
Collapse
|
16
|
Xu Y, Sudharshan L, Hsu MA, Koenig AS, Cappelleri JC, Liu WF, Smith TW, Pasquale MK. Patient Preferences Associated with Therapies for Psoriatic Arthritis: A Conjoint Analysis. AMERICAN HEALTH & DRUG BENEFITS 2018; 11:408-417. [PMID: 30647828 PMCID: PMC6306099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 01/09/2018] [Accepted: 06/01/2018] [Indexed: 06/09/2023]
Abstract
BACKGROUND As psoriatic arthritis (PsA) treatment choices continue to expand, it is important to consider patient preferences for treatment modalities for PsA. Involving patients in treatment decisions can influence adherence to treatment and outcomes of therapy. OBJECTIVE To determine patient preferences for medication attributes prescribed for patients with PsA. METHODS A choice-based conjoint survey was mailed to 2800 randomly selected patients with PsA who were enrolled in Humana Medicare and commercial plans. Patients had been diagnosed with PsA between January 1, 2012, and September 30, 2016. The medication attributes included in the survey were the medication route of administration, frequency of administration, ability to reduce daily joint pain and swelling, likelihood of serious infections, improvement in the patient's ability to perform daily activities, achieving clear or almost clear skin, and cost. Hierarchical Bayesian models were used to score patient preferences after adjusting for demographic and clinical characteristics. The mean attribute importance scores were used to rank patient preferences. RESULTS A total of 468 patients (258 with a Medicare plan and 210 with a commercial plan) completed the survey. The top 3 medication attributes for patients in Medicare plans were route of administration, cost, and improvement in the ability to perform daily activities. For patients in commercial plans, the top 3 medication attributes were cost, route of administration, and frequency of administration. Within the top 2 attributes for patients in both plans, the oral route of administration and lower cost were most preferred. CONCLUSION Medication route of administration and cost were the 2 most important considerations for patients diagnosed with PsA who were enrolled in Medicare or commercial plans with Humana. As PsA treatment choices continue to expand, considering patient preferences may improve patient adherence and treatment outcomes and should be considered when making treatment decisions for this patient population.
Collapse
Affiliation(s)
- Yihua Xu
- Research Science Lead, Comprehensive Health Insights, Humana, Louisville, KY
| | - Lavanya Sudharshan
- Research Consultant, Comprehensive Health Insights, Humana, during the study
| | - Ming-Ann Hsu
- Sr. Director, Health Economics & Outcomes Research, Patient & Health Impact, Inflammation & Immunology, Pfizer, Groton, CT
| | - Andrew S Koenig
- Inflammation & Immunology Group Lead, N. American Medical Affairs, Pfizer, Collegeville, CT
| | | | - Wen F Liu
- Clinical Pharmacist, Humana Pharmacy Solutions Clinical Strategies, Humana
| | - Timothy W Smith
- Director, Real World Data & Analytics, Patient & Health Impact, Pfizer, New York, NY
| | | |
Collapse
|
17
|
Palominos PE, Gossec L, Kreis S, Hinckel CL, da Silva Chakr RM, Moro ALD, Campbell W, de Wit M, Goel N, Kohem CL, Xavier RM. The effects of cultural background on patient-perceived impact of psoriatic arthritis - a qualitative study conducted in Brazil and France. Adv Rheumatol 2018; 58:33. [PMID: 30657095 DOI: 10.1186/s42358-018-0036-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2018] [Accepted: 10/08/2018] [Indexed: 01/28/2023] Open
Abstract
BACKGROUND In psoriatic arthritis (PsA) almost all qualitative studies have been performed in European populations. This work aimed to evaluate the impact of PsA in Brazilian and French subjects, as well as to explore cultural differences in the experience of disease and to recognize domains important for patients living with PsA outside Europe. METHODS A qualitative study was conducted in two university hospitals in Brazil and France; outpatients fulfilling Classification Criteria for PsA participated in individual interviews regarding the impact of PsA; interviews were conducted in the local language. The sample size was defined by saturation; interviews were recorded and transcribed and content analysis was performed. RESULTS Fifteen patients were interviewed in Brazil and 13 in France. Mean disease duration was 16.5 ± 12.5 years (range: 8 months to 47 years) and 14.4 ± 8.4 years (range 12 months to 29 years) for Brazilian and French subjects, respectively. A broad impact was perceived: 67 codes emerged from the interviews and were grouped in 41 categories. Although 2/3 of categories were common to both nationalities, some important health domains from the perspective of PsA patients from a non-European background were brought to light including sexual dysfunction, emotional impact of psoriasis and impact of prejudice on social and professional life. CONCLUSIONS This study highlights the importance of assessing the impact of PsA on a national level, emphasizing the common cross-cultural aspects but also revealing domains of interest for patients with PsA living outside Europe which merit further study.
Collapse
Affiliation(s)
- Penélope Esther Palominos
- Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Ramiro Barcelos Street 2350, Porto Alegre, Zip code 90035903, Brazil. .,Programa de Pós Graduação em Ciências Médicas, Universidade Federal do Rio Grande do Sul (UFRGS), Ramiro Barcelos 2400, Porto Alegre, Zip code 90035903, Brazil.
| | - Laure Gossec
- Institut Pierre Louis d'Epidémiologie et de Santé Publique. Pitié-Salpetrière Hospital, AP-HP, Rheumatology Department, Sorbonne Universités, UPMC Univ Paris 6, GRC-08, 83 Boulevard de l'Hôpital, 75013, Paris, France
| | - Sarah Kreis
- Institut Pierre Louis d'Epidémiologie et de Santé Publique. Pitié-Salpetrière Hospital, AP-HP, Rheumatology Department, Sorbonne Universités, UPMC Univ Paris 6, GRC-08, 83 Boulevard de l'Hôpital, 75013, Paris, France
| | - César Luis Hinckel
- Faculdade de Medicina, Departamento de Medicina Interna, Universidade Federal do Rio Grande do Sul (UFRGS), Ramiro Barcelos 2400, Porto Alegre, Zip code 90035903, Brazil
| | - Rafael Mendonça da Silva Chakr
- Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Ramiro Barcelos Street 2350, Porto Alegre, Zip code 90035903, Brazil.,Programa de Pós Graduação em Ciências Médicas, Universidade Federal do Rio Grande do Sul (UFRGS), Ramiro Barcelos 2400, Porto Alegre, Zip code 90035903, Brazil.,Faculdade de Medicina, Departamento de Medicina Interna, Universidade Federal do Rio Grande do Sul (UFRGS), Ramiro Barcelos 2400, Porto Alegre, Zip code 90035903, Brazil
| | - Ana Laura Didonet Moro
- Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Ramiro Barcelos Street 2350, Porto Alegre, Zip code 90035903, Brazil
| | - Willemina Campbell
- Patient Research Partner, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), University Health Network, Toronto Western Hospital, 399 Street Toronto, Bathurst, ON, M5T 2S8, Canada
| | - Maarten de Wit
- Department of Medical Humanities, Patient Research Partner, VU University Medical Centre, de Boelenlaan 1089a, 1081 HV, Amsterdam, Netherlands
| | - Niti Goel
- Patient Research Partner; Advisory Services, Quintiles; Division of Rheumatology, Duke University School of Medicine, Durham, North Carolina, 27705, USA
| | - Charles Lubianca Kohem
- Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Ramiro Barcelos Street 2350, Porto Alegre, Zip code 90035903, Brazil.,Faculdade de Medicina, Departamento de Medicina Interna, Universidade Federal do Rio Grande do Sul (UFRGS), Ramiro Barcelos 2400, Porto Alegre, Zip code 90035903, Brazil
| | - Ricardo Machado Xavier
- Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Ramiro Barcelos Street 2350, Porto Alegre, Zip code 90035903, Brazil.,Programa de Pós Graduação em Ciências Médicas, Universidade Federal do Rio Grande do Sul (UFRGS), Ramiro Barcelos 2400, Porto Alegre, Zip code 90035903, Brazil.,Faculdade de Medicina, Departamento de Medicina Interna, Universidade Federal do Rio Grande do Sul (UFRGS), Ramiro Barcelos 2400, Porto Alegre, Zip code 90035903, Brazil
| |
Collapse
|
18
|
Leung YY, Ogdie A, Orbai AM, Tillett W, Coates LC, Strand V, Mease P, Gladman DD. Classification and Outcome Measures for Psoriatic Arthritis. Front Med (Lausanne) 2018; 5:246. [PMID: 30238006 PMCID: PMC6135872 DOI: 10.3389/fmed.2018.00246] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2018] [Accepted: 08/15/2018] [Indexed: 12/22/2022] Open
Abstract
Psoriatic arthritis (PsA) is an inflammatory arthritis with multiple manifestations: peripheral/axial arthritis, enthesitis, dactylitis, psoriasis, and nail involvement. From having an agreed upon classification criteria in 2006, the assessment of PsA has advanced from uncertainties to development and validation of numerous specific outcome measures. The Group for Research and Assessment of Psoriasis and Psoriatic arthritis (GRAPPA) has spearheaded the development of a core domain set and is now working on a core outcome measurement set to standardize outcome measures for PsA, that will provide guidance for use of instruments in randomized controlled trials (RCTs) and longitudinal observational studies (LOS). This article summarizes and updates these work processes to improve assessment of this multisystem complex rheumatologic disease.
Collapse
Affiliation(s)
- Ying Ying Leung
- Department of Rheumatology and Immunology, Singapore General Hospital, Duke-NUS Medical School, Singapore, Singapore
| | - Alexis Ogdie
- Division of Rheumatology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, United States
| | - Ana-Maria Orbai
- Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, United States
| | - William Tillett
- Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
| | - Laura C. Coates
- Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
| | - Vibeke Strand
- Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, United States
| | - Philip Mease
- Department of Rheumatology Research, Swedish Medical Center, University of Washington, Seattle, WA, United States
| | - Dafna D. Gladman
- Division of Rheumatology and Krembil Research Institute, University Health Network, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
19
|
Affiliation(s)
- Tania Gudu
- Research Center of Rheumatic Diseases, Sf Maria Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
| | - Laure Gossec
- Department of Rheumatology, Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique; AP-HP, Pitié Salpêtrière Hospital, Paris, France
| |
Collapse
|
20
|
Højgaard P, Klokker L, Orbai AM, Holmsted K, Bartels EM, Leung YY, Goel N, de Wit M, Gladman DD, Mease P, Dreyer L, Kristensen LE, FitzGerald O, Tillett W, Gossec L, Helliwell P, Strand V, Ogdie A, Terwee CB, Christensen R. A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. Semin Arthritis Rheum 2018; 47:654-665. [DOI: 10.1016/j.semarthrit.2017.09.002] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2017] [Accepted: 09/06/2017] [Indexed: 01/10/2023]
|
21
|
Ogdie A, de Wit M, Callis Duffin K, Campbell W, Chau J, Coates LC, Eder L, Elmamoun M, FitzGerald O, Gladman DD, Goel N, James J, Kalyoncu U, Latella J, Lindsay C, Mease PJ, O'Sullivan D, Steinkoenig I, Strand V, Tillett W, Orbai AM. Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. J Rheumatol 2018; 44:697-700. [PMID: 28461531 DOI: 10.3899/jrheum.170150] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group recently published the updated 2016 psoriatic arthritis (PsA) core domain set, a set of disease features that should be measured in all clinical trials. At the GRAPPA annual meeting in July 2016, the PsA working group presented the updated PsA core domain set endorsed by 90% of participants at OMERACT in May 2016 and drafted a roadmap for the development of the PsA core outcome measurement set. In this manuscript, we review the development process of the PsA core domain set and the ongoing and proposed work streams for development of a PsA core measurement set.
Collapse
Affiliation(s)
- Alexis Ogdie
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey. .,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center.
| | - Maarten de Wit
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center
| | - Kristina Callis Duffin
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center
| | - Willemina Campbell
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center
| | - Jeffrey Chau
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center
| | - Laura C Coates
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center
| | - Lihi Eder
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center
| | - Musaab Elmamoun
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center
| | - Oliver FitzGerald
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center
| | - Dafna D Gladman
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center
| | - Niti Goel
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center
| | - Jana James
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center
| | - Umut Kalyoncu
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center
| | - John Latella
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center
| | - Chris Lindsay
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center
| | - Philip J Mease
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center
| | - Denis O'Sullivan
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center
| | - Ingrid Steinkoenig
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center
| | - Vibeke Strand
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center
| | - William Tillett
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center
| | - Ana-Maria Orbai
- From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.,A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center
| |
Collapse
|
22
|
Husni ME, Merola JF, Davin S. The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum 2017; 47:351-360. [DOI: 10.1016/j.semarthrit.2017.05.010] [Citation(s) in RCA: 95] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2017] [Revised: 05/09/2017] [Accepted: 05/19/2017] [Indexed: 01/01/2023]
|
23
|
Abstract
PURPOSE OF THE REVIEW We will address current treatment and unmet needs in psoriatic arthritis (PsA), examine existing randomized controlled trials (RCTs), and consider options for new trial designs and challenges in their implementation. RECENT FINDINGS While therapeutic options for PsA have rapidly increased, there continues to be a need for clinical trials to test new therapies and establish optimal treatment strategies in order to improve the care for patients with PsA. In addition, more data is needed on how to select the best therapy for a given patient in clinical practice. Consideration of alternative outcome measures is also needed. Despite the rapid expansion in the number of therapy options available, there is still much to be learned about how to treat the individual patient with PsA.
Collapse
Affiliation(s)
- Alexis Ogdie
- Division of Rheumatology, Departments of Medicine and Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, White Building Room 5023, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA.
| | - Laura Coates
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK
| |
Collapse
|
24
|
Orbai AM, de Wit M, Mease PJ, Callis Duffin K, Elmamoun M, Tillett W, Campbell W, FitzGerald O, Gladman DD, Goel N, Gossec L, Hoejgaard P, Leung YY, Lindsay C, Strand V, van der Heijde DM, Shea B, Christensen R, Coates L, Eder L, McHugh N, Kalyoncu U, Steinkoenig I, Ogdie A. Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. J Rheumatol 2017; 44:1522-1528. [PMID: 28148697 PMCID: PMC5538953 DOI: 10.3899/jrheum.160904] [Citation(s) in RCA: 81] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/20/2016] [Indexed: 01/31/2023]
Abstract
OBJECTIVE To include the patient perspective in accordance with the Outcome Measures in Rheumatology (OMERACT) Filter 2.0 in the updated Psoriatic Arthritis (PsA) Core Domain Set for randomized controlled trials (RCT) and longitudinal observational studies (LOS). METHODS At OMERACT 2016, research conducted to update the PsA Core Domain Set was presented and discussed in breakout groups. The updated PsA Core Domain Set was voted on and endorsed by OMERACT participants. RESULTS We conducted a systematic literature review of domains measured in PsA RCT and LOS, and identified 24 domains. We conducted 24 focus groups with 130 patients from 7 countries representing 5 continents to identify patient domains. We achieved consensus through 2 rounds of separate surveys with 50 patients and 75 physicians, and a nominal group technique meeting with 12 patients and 12 physicians. We conducted a workshop and breakout groups at OMERACT 2016 in which findings were presented and discussed. The updated PsA Core Domain Set endorsed with 90% agreement by OMERACT 2016 participants included musculoskeletal disease activity, skin disease activity, fatigue, pain, patient's global assessment, physical function, health-related quality of life, and systemic inflammation, which were recommended for all RCT and LOS. These were important, but not required in all RCT and LOS: economic cost, emotional well-being, participation, and structural damage. Independence, sleep, stiffness, and treatment burden were on the research agenda. CONCLUSION The updated PsA Core Domain Set was endorsed at OMERACT 2016. Next steps for the PsA working group include evaluation of PsA outcome measures and development of a PsA Core Outcome Measurement Set.
Collapse
Affiliation(s)
- Ana-Maria Orbai
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey.
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania.
| | - Maarten de Wit
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Philip J Mease
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Kristina Callis Duffin
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Musaab Elmamoun
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - William Tillett
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Willemina Campbell
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Oliver FitzGerald
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Dafna D Gladman
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Niti Goel
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Laure Gossec
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Pil Hoejgaard
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Ying Ying Leung
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Chris Lindsay
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Vibeke Strand
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Désirée M van der Heijde
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Bev Shea
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Robin Christensen
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Laura Coates
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Lihi Eder
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Neil McHugh
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Umut Kalyoncu
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Ingrid Steinkoenig
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| | - Alexis Ogdie
- From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
- A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania
| |
Collapse
|
25
|
Desthieux C, Granger B, Balanescu AR, Balint P, Braun J, Canete JD, Heiberg T, Helliwell PS, Kalyoncu U, Kvien TK, Kiltz U, Niedermayer D, Otsa K, Scrivo R, Smolen J, Stamm TA, Veale DJ, de Vlam K, de Wit M, Gossec L. Determinants of Patient-Physician Discordance in Global Assessment in Psoriatic Arthritis: A Multicenter European Study. Arthritis Care Res (Hoboken) 2017; 69:1606-1611. [DOI: 10.1002/acr.23172] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2016] [Revised: 11/22/2016] [Accepted: 12/13/2016] [Indexed: 01/18/2023]
Affiliation(s)
- Carole Desthieux
- Sorbonne Universités, UPMC University Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Hôpital Pitié Salpêtrière; Paris France
| | - Benjamin Granger
- Sorbonne Universités, UPMC University Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Hôpital Pitié Salpêtrière; Paris France
| | - Andra Rodica Balanescu
- University of Medicine and Pharmacy Carol Davila and St Maria Hospital; Bucharest Romania
| | - Peter Balint
- National Institute of Rheumatology and Physiotherapy; Budapest Hungary
| | - Jürgen Braun
- Ruhrgebiet, Herne and Ruhr-Universität Bochum; Herne Germany
| | | | - Turid Heiberg
- Østfold University College, Halden, and Regional Research Support, Oslo University Hospital; Oslo Norway
| | | | | | | | - Uta Kiltz
- Ruhrgebiet, Herne and Ruhr-Universität Bochum; Herne Germany
| | - Dora Niedermayer
- National Institute of Rheumatology and Physiotherapy; Budapest Hungary
| | - Kati Otsa
- Tallinn Central Hospital; Tallinn Estonia
| | | | - Josef Smolen
- III Medical University of Vienna; Vienna Austria
| | | | - Douglas J. Veale
- Dublin Academic Medical Centre and St Vincent's University Hospital; Dublin Ireland
| | | | - Maarten de Wit
- Patient Research Partner, People with Arthritis/Rheumatism in Europe; Zurich Switzerland
| | - Laure Gossec
- Sorbonne Universités, UPMC University Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Hôpital Pitié Salpêtrière; Paris France
| |
Collapse
|
26
|
Dures E, Hewlett S, Lord J, Bowen C, McHugh N, Tillett W. Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study. THE PATIENT 2017; 10:455-462. [PMID: 28229377 PMCID: PMC5534194 DOI: 10.1007/s40271-017-0221-4] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
BACKGROUND Psoriatic arthritis (PsA) is a variable and complex inflammatory condition. Symptoms can compromise physical function, reduce quality of life, and accrue significant health costs. Commonly used patient-reported outcomes largely reflect the professionals' perspective, however it is not known whether they capture what is important to patients. OBJECTIVE The aim of our study was to identify treatment outcomes important to patients with PsA. METHODS Eight focus groups that were audio recorded, transcribed, anonymised and analysed using inductive thematic analysis were conducted at five hospital sites. The full data set was analysed by the lead researcher, and subsets analysed by three team members (including patient partners). RESULTS Overall, 41 patients sampled for a range of phenotypes and domains of disease activity participated in the study: 20 males; mean age 58 years (range 28-75, standard deviation [SD] 11.4); mean disease duration 9 years (range 0.5-39, SD 8.3); and mean Health Assessment Questionnaire score of 1 (range 0.0-2.5, SD 0.7). Over 60 outcomes were identified and grouped into four themes: (i) symptom alleviation (e.g. pain, fatigue, itchy skin, swelling, and reducing variability); (ii) reduction of disease impact (e.g. tiredness and pain, mobility and dexterity, deteriorating physical fitness, negative emotional responses, and strained relationships and social interactions); (iii) improved prognosis (e.g. slowing down disease progression, maintaining independence, and enhancing quality of life); and (iv) minimisation of treatment harm and burden (e.g. nausea, long-term effects, and administration and monitoring of treatments). CONCLUSIONS Outcomes from treatments that are important to patients, which relate to impacts from PsA and its treatment that range beyond those outcomes commonly measured, were identified. These patient perspectives need to be considered when evaluating treatments.
Collapse
Affiliation(s)
- Emma Dures
- University of the West of England, Bristol, UK.
- Academic Rheumatology, Bristol Royal Infirmary, Bristol, BS2 8HW, UK.
| | | | - Jane Lord
- University Hospitals Bristol, Bristol, UK
| | - Clive Bowen
- The Psoriatic Arthritis Support Group (PsAZZ), Bath, UK
| | | | | |
Collapse
|
27
|
Tillett W, Orbai AM, Ogdie A, Leung YY, Strand V, Gladman DD, Mease PJ, Coates LC. GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies. Ann Rheum Dis 2017; 77:e23. [DOI: 10.1136/annrheumdis-2017-212004] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2017] [Accepted: 06/30/2017] [Indexed: 01/09/2023]
|
28
|
Ramiro S, Smolen JS, Landewé R, Heijde DVD, Gossec L. How are enthesitis, dactylitis and nail involvement measured and reported in recent clinical trials of psoriatic arthritis? A systematic literature review. Ann Rheum Dis 2017; 77:782-783. [PMID: 28584188 DOI: 10.1136/annrheumdis-2017-211447] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2017] [Revised: 04/24/2017] [Accepted: 05/08/2017] [Indexed: 11/04/2022]
Affiliation(s)
- Sofia Ramiro
- Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
| | - Josef S Smolen
- Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria.,Department of Medicine, Hietzing Hospital, Vienna, Austria
| | - Robert Landewé
- Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam and Zuyderland Hospital, Heerlen, The Netherlands
| | | | - Laure Gossec
- Department of Rheumatology, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Paris, France
| |
Collapse
|
29
|
Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, Tillett W, Elmamoun M, Callis Duffin K, Campbell W, Christensen R, Coates L, Dures E, Eder L, FitzGerald O, Gladman D, Goel N, Grieb SD, Hewlett S, Hoejgaard P, Kalyoncu U, Lindsay C, McHugh N, Shea B, Steinkoenig I, Strand V, Ogdie A. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis 2016; 76:673-680. [PMID: 27613807 PMCID: PMC5344772 DOI: 10.1136/annrheumdis-2016-210242] [Citation(s) in RCA: 167] [Impact Index Per Article: 20.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2016] [Revised: 08/10/2016] [Accepted: 08/21/2016] [Indexed: 02/02/2023]
Abstract
Objective To identify a core set of domains (outcomes) to be measured in psoriatic arthritis (PsA) clinical trials that represent both patients' and physicians' priorities. Methods We conducted (1) a systematic literature review (SLR) of domains assessed in PsA; (2) international focus groups to identify domains important to people with PsA; (3) two international surveys with patients and physicians to prioritise domains; (4) an international face-to-face meeting with patients and physicians using the nominal group technique method to agree on the most important domains; and (5) presentation and votes at the Outcome Measures in Rheumatology (OMERACT) conference in May 2016. All phases were performed in collaboration with patient research partners. Results We identified 39 unique domains through the SLR (24 domains) and international focus groups (34 domains). 50 patients and 75 physicians rated domain importance. During the March 2016 consensus meeting, 12 patients and 12 physicians agreed on 10 candidate domains. Then, 49 patients and 71 physicians rated these domains' importance. Five were important to >70% of both groups: musculoskeletal disease activity, skin disease activity, structural damage, pain and physical function. Fatigue and participation were important to >70% of patients. Patient global and systemic inflammation were important to >70% of physicians. The updated PsA core domain set endorsed by 90% of OMERACT 2016 participants includes musculoskeletal disease activity, skin disease activity, pain, patient global, physical function, health-related quality of life, fatigue and systemic inflammation. Conclusions The updated PsA core domain set incorporates patients' and physicians' priorities and evolving PsA research. Next steps include identifying outcome measures that adequately assess these domains.
Collapse
Affiliation(s)
- Ana-Maria Orbai
- Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Maarten de Wit
- Department of Medical Humanities, Patient Research Partner, VU University Medical Centre, Amsterdam, The Netherlands
| | - Philip Mease
- Swedish Medical Center and University of Washington, Seattle, Washington, USA
| | - Judy A Shea
- University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Laure Gossec
- Sorbonne Universités, UPMC Univ Paris 06, GRC-08, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.,Rheumatology Department, Pitie-Salpétrière Hôpital, AP-HP, Paris, France
| | - Ying Ying Leung
- Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
| | - William Tillett
- Royal National Hospital for Rheumatic Diseases and the University of Bath, Bath, UK
| | - Musaab Elmamoun
- St. Vincent's University Hospital and the Conway Institute, University College Dublin (UCD), Dublin, Ireland
| | | | | | - Robin Christensen
- The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark, Denmark
| | - Laura Coates
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Emma Dures
- Department of Nursing, University of the West of England, Bristol, UK
| | - Lihi Eder
- Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada
| | - Oliver FitzGerald
- St. Vincent's University Hospital and the Conway Institute, University College Dublin (UCD), Dublin, Ireland
| | - Dafna Gladman
- Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
| | - Niti Goel
- Patient Research Partner, Advisory Services, Quintiles, Durham, North Carolina, USA.,Division of Rheumatology, Duke University School of Medicine, Durham, North Carolina, USA
| | | | - Sarah Hewlett
- Department of Nursing, University of the West of England, Bristol, UK
| | - Pil Hoejgaard
- The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark, Denmark
| | - Umut Kalyoncu
- Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.,Division of Rheumatology, Hacettepe University, Ankara, Turkey
| | - Chris Lindsay
- Patient Research Partner, Thousand Oaks, California, USA
| | - Neil McHugh
- Royal National Hospital for Rheumatic Diseases and the University of Bath, Bath, UK
| | - Bev Shea
- Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada
| | | | - Vibeke Strand
- Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA
| | - Alexis Ogdie
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| |
Collapse
|
30
|
Højgaard P, Christensen R, Dreyer L, Mease P, de Wit M, Skov L, Glintborg B, Christensen AW, Ballegaard C, Bliddal H, Bukhave K, Bartels EM, Amris K, Ellegaard K, Kristensen LE. Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: protocol for a prospective, exploratory cohort study. BMJ Open 2016; 6:e010650. [PMID: 27084281 PMCID: PMC4838702 DOI: 10.1136/bmjopen-2015-010650] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
INTRODUCTION Persistent pain is a major concern for patients with psoriatic arthritis (PsA). Pain may be due to inflammatory activity or augmented central pain processing. Unawareness of the origin and mechanisms of pain can lead to misinterpretation of disease activity (by composite scores) and erroneous treatments. Ultrasonography (US) is a highly sensitive method to detect tissue inflammation. Evaluating pain mechanisms in relation to US measures may prove valuable in predicting response to treatment in PsA. AIMS To study the association and prognostic value of pain mechanisms, ultrasonic activity and clinical outcomes in patients with PsA who intensify antirheumatic treatment. METHODS AND ANALYSES 100 participants >18 years of age with PsA who initiate or switch antirheumatic treatment (biologicals and/or conventional synthetic disease-modifying antirheumatic drugs (DMARDs)) will be prospectively recruited from outpatient clinics in Copenhagen. All data (demographics, clinical, imaging, blood samples and patient-reported outcomes) will be collected at baseline and after 4 months. Pain is assessed by the PainDETECT Questionnaire, Visual Analogue Scale for pain, Swollen to Tender Joint Count Ratio, Widespread Pain Index and tender point examination. The association between pain variables and clinical/US characteristics will be described by correlation analyses. The predictive value of pain measures and baseline US scores on treatment response will be analysed with regression models. Outcomes are composite and clinical, as well as patient reported. ETHICS AND DISSEMINATION The study is approved by the ethics committee of the Capital Region of Denmark (H-15009080) and has been designed in cooperation with patient research partners. The study is registered at clinicaltrials.gov (number NCT02572700). Results will be disseminated through publication in international peer-reviewed journals. TRIAL REGISTRATION NUMBER NCT02572700, Pre-results.
Collapse
Affiliation(s)
- Pil Højgaard
- Bispebjerg and Frederiksberg Hospital, The Parker Institute, Frederiksberg, Denmark
- Department of Rheumatology, Herlev and Gentofte Hospital, Hellerup, Denmark
| | - Robin Christensen
- Bispebjerg and Frederiksberg Hospital, The Parker Institute, Frederiksberg, Denmark
| | - Lene Dreyer
- Bispebjerg and Frederiksberg Hospital, The Parker Institute, Frederiksberg, Denmark
- Department of Rheumatology, Herlev and Gentofte Hospital, Hellerup, Denmark
| | - Philip Mease
- Swedish Medical Center, University of Washington, Seattle, Washington, USA
| | - Maarten de Wit
- Department of Medical Humanities, VU University Medical Centre, Amsterdam, The Netherlands
| | - Lone Skov
- Department of Dermato-Allergology, Herlev and Gentofte Hospital, Hellerup, Denmark
- Faculty of health and medical sciences, University of Copenhagen, Copenhagen, Denmark
| | - Bente Glintborg
- Department of Rheumatology, Herlev and Gentofte Hospital, Hellerup, Denmark
| | | | - Christine Ballegaard
- Bispebjerg and Frederiksberg Hospital, The Parker Institute, Frederiksberg, Denmark
| | - Henning Bliddal
- Bispebjerg and Frederiksberg Hospital, The Parker Institute, Frederiksberg, Denmark
- Faculty of health and medical sciences, University of Copenhagen, Copenhagen, Denmark
| | - Kristine Bukhave
- Department of Dermato-Allergology, Herlev and Gentofte Hospital, Hellerup, Denmark
| | - Else Marie Bartels
- Bispebjerg and Frederiksberg Hospital, The Parker Institute, Frederiksberg, Denmark
| | - Kirstine Amris
- Bispebjerg and Frederiksberg Hospital, The Parker Institute, Frederiksberg, Denmark
| | - Karen Ellegaard
- Bispebjerg and Frederiksberg Hospital, The Parker Institute, Frederiksberg, Denmark
| | - Lars Erik Kristensen
- Bispebjerg and Frederiksberg Hospital, The Parker Institute, Frederiksberg, Denmark
| |
Collapse
|